The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 22 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell".
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy".
Wall Street's median 12-month price target for Insulet Corporation is $241.00, about 44.5% above its August 4 closing price of $166.82.
The stock recently traded at 23 times the next 12-month earnings vs. a P/E of 25 three months ago.
PODD•
